145 related articles for article (PubMed ID: 27595248)
21. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin.
Göke B; Hershon K; Kerr D; Calle Pascual A; Schweizer A; Foley J; Shao Q; Dejager S
Horm Metab Res; 2008 Dec; 40(12):892-5. PubMed ID: 18726829
[TBL] [Abstract][Full Text] [Related]
22. A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation.
Haidinger M; Werzowa J; Voigt HC; Pleiner J; Stemer G; Hecking M; Döller D; Hörl WH; Weichhart T; Säemann MD
Trials; 2010 Oct; 11():91. PubMed ID: 20925938
[TBL] [Abstract][Full Text] [Related]
23. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
24. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.
Strain WD; Lukashevich V; Kothny W; Hoellinger MJ; Paldánius PM
Lancet; 2013 Aug; 382(9890):409-416. PubMed ID: 23706759
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
Kim G; Oh S; Jin SM; Hur KY; Kim JH; Lee MK
Expert Opin Pharmacother; 2017 Aug; 18(12):1179-1186. PubMed ID: 28714741
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin and low-dose metformin.
Suzuki L; Kanazawa A; Uzawa H; Osonoi Y; Masuyama A; Azuma K; Takeno K; Takayanagi N; Sato J; Someya Y; Komiya K; Goto H; Mita T; Ikeda F; Ogihara T; Shimizu T; Ohmura C; Saito M; Osonoi T; Watada H
Expert Opin Pharmacother; 2017 Dec; 18(18):1921-1928. PubMed ID: 29141460
[TBL] [Abstract][Full Text] [Related]
27. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
Filozof C; Gautier JF
Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
[TBL] [Abstract][Full Text] [Related]
28. Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study.
Rosales R; Abou Jaoude E; Al-Arouj M; Fawwad A; Orabi A; Shah P; DiTommaso S; Vaz J; Latif ZA
Diabetes Obes Metab; 2015 Jun; 17(6):603-607. PubMed ID: 25586779
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting.
Melzer Cohen C; Davis C; Shalev V; Chodick G
J Diabetes; 2018 Jan; 10(1):68-72. PubMed ID: 28418203
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study.
Ji LN; Pan CY; Lu JM; Li H; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Zhang RY; Wang XL; Wang L;
Cardiovasc Diabetol; 2013 Aug; 12():118. PubMed ID: 23958390
[TBL] [Abstract][Full Text] [Related]
31. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.
Dejager S; Razac S; Foley JE; Schweizer A
Horm Metab Res; 2007 Mar; 39(3):218-23. PubMed ID: 17373638
[TBL] [Abstract][Full Text] [Related]
32. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study.
Al-Arouj M; Hassoun AA; Medlej R; Pathan MF; Shaltout I; Chawla MS; Hristoskova S; Ditommaso S; Kadwa MY
Int J Clin Pract; 2013 Oct; 67(10):957-63. PubMed ID: 24001317
[TBL] [Abstract][Full Text] [Related]
33. Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus.
Strózik A; Stęposz A; Basiak M; Drożdż M; Okopień B
Pharmacol Rep; 2015 Feb; 67(1):24-31. PubMed ID: 25560571
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
Li CJ; Yu Q; Yu P; Zhang QM; Ding M; Liu XJ; Yu DM
Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):469-76. PubMed ID: 24838155
[TBL] [Abstract][Full Text] [Related]
35. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes.
Foley JE; Sreenan S
Horm Metab Res; 2009 Dec; 41(12):905-9. PubMed ID: 19705345
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
Lukashevich V; Schweizer A; Foley JE; Dickinson S; Groop PH; Kothny W
Vasc Health Risk Manag; 2013; 9():21-8. PubMed ID: 23378769
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Mikhail N
Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
[TBL] [Abstract][Full Text] [Related]
39. Vildagliptin more effectively achieves a composite endpoint of HbA₁c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment.
Bader G; Geransar P; Schweizer A
Diabetes Res Clin Pract; 2013 Jun; 100(3):e78-81. PubMed ID: 23538267
[TBL] [Abstract][Full Text] [Related]
40. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
Garber AJ; Schweizer A; Baron MA; Rochotte E; Dejager S
Diabetes Obes Metab; 2007 Mar; 9(2):166-74. PubMed ID: 17300592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
